

Supplementary Information for

**Induction of innate and adaptive immunity by delivery of poly dA:dT  
to dendritic cells**


Scott Barbuto<sup>1-3,5</sup>, Juliana Idoyaga<sup>2,3,5</sup>, Miquel Vila-Perelló<sup>1,4</sup>, Maria P. Longhi<sup>2,3</sup>,  
Gaëlle Breton<sup>2,3</sup>, Ralph M. Steinman<sup>2,3,6</sup>, Tom W. Muir<sup>1,4\*</sup>

<sup>1</sup>Laboratory of Synthetic Protein Chemistry, The Rockefeller University, New York, New York, USA. <sup>2</sup>Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York, USA. <sup>3</sup>Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, New York, USA. <sup>4</sup>Present address: Department of Chemistry, Frick Chemistry Laboratory, Princeton University, Princeton, New Jersey, USA. <sup>5</sup>S.B. and J.I. contributed equally to this work. <sup>6</sup>R.M.S. regrettably passed away on September 30, 2011.

\*Address correspondence to Dr. Tom W. Muir. E-mail address: [muir@princeton.edu](mailto:muir@princeton.edu)


# Supplementary Results

## Supplementary Figure 1




**Supplementary Figure 1. Production of mAb-intein conjugates, and MESNA treatment.** (a) Production of mAb-intein fusions. 10% SDS-PAGE gel stained with Coomassie blue of the purified mAb-intein constructs used in this study (h corresponds to human and m to mouse constructs). The purified uncoupled  $\alpha$ -mDEC mAb is shown for comparison. Numbers are expressed in kDa. (b) Western blot analysis of the various mAb-intein constructs used in the study employing either  $\alpha$ -human or  $\alpha$ -mouse secondary Ab conjugated with HRP. Numbers are expressed in kDa. (c) Binding of different doses (2, 0.2 and 0.02  $\mu$ g) of unconjugated  $\alpha$ -mDEC,  $\alpha$ -mDEC-intein, and  $\alpha$ -mDEC-pdA:dT mAbs to CHO cells expressing mouse DEC205 (CHO/mDEC; green) and control CHO/NEO (gray) cells as monitored by flow cytometry after staining with PE-conjugated  $\alpha$ -mouse IgG mAbs. (d) Time course of the MESNA thiolysis reaction of the  $\alpha$ -hDEC205-intein mAbs. The reaction was complete by 24 hrs yielding the  $\alpha$ -thioester derivative of the mAb heavy chain (expected mass = ~50 kDa). Numbers are expressed in kDa. (e) The mAb-intein fusions were treated with MESNA for 18 hrs to give  $\alpha$ -thioester derivatives. Thiolysis of the intein from the heavy chain was monitored by 10% SDS-PAGE stained with Coomassie blue. Numbers are expressed in kDa.

## Supplementary Figure 2




**Supplementary Figure 2. RP-HPLC, MS, and SEC-MALS analysis of  $\alpha$ -hDEC mAbs.** (a) RP-HPLC of deglycosylated and reduced MESNA-treated  $\alpha$ -hDEC mAbs. Sample was analyzed on a C4 column using a linear gradient of 5-75% solvent D in solvent C over 30 min at 55 °C and monitored at 280 nm. (b & c) Representative MS for the light (b) and heavy chains (c) are shown. For the light chain, the detected MW was in good agreement with its calculated value of 23398.09 Da. For the heavy chain a MW corresponding to the C-terminal carboxylate was detected ( $MW_{\text{calcd}} = 49823.2$  Da). Hydrolysis of the C-terminal MESNA thioester was expected due to sample preparation prior to RP-HPLC and MS analysis, which included deglycosylation (18 h at 37 °C, pH 7.5 in the absence of thiols) and reduction (6 M Gn·HCl, 10 mM DTT, pH 7.5 for 1-2 h at 37 °C). (d & e) MESNA treated  $\alpha$ -hDEC mAbs was analyzed by SEC-MALS 24 h after ligation (d) as well as after removal of intein and storage at 4°C for 2 weeks (e). Both samples show a mono-disperse peak (poly-dispersity index = 1.002) with a measured MW of 155-159 kDa, in agreement with the calculated size for the tetrameric IgG (148 kDa).

### Supplementary Figure 3




**Supplementary Figure 3. Model EPL of  $\alpha$ -DEC mAbs and a fluorescent peptide.** (a) 100 pmoles of MESNA-treated  $\alpha$ -hDEC mAbs were reacted for 18 hrs in ligation buffer (1x PBS, 400 mM NaCl, 6 mM TCEP, 1 mM EDTA, 100 mM MESNA, pH 7.5) with 1 nmol of a short fluorescent-labeled peptide (H-Cys-Gly-Lys[<sup>ε</sup>N-Fluorescein]-Gly-NH<sub>2</sub>). The mixture was then resolved by 10% SDS PAGE, imaged using a fluorescent scanner, and analyzed using ImageJ software to quantify the band intensities. To quantify the amount of fluorescent-labeled mAbs, a standard curve was generated by running the fluorescent peptide at varying concentrations on the same gel. Quantification indicated that the ligation efficiency was >90% (based on the amount of reactive mAb starting material). R is mAb ligation reaction. (b) RP-HPLC analysis of deglycosylated and reduced  $\alpha$ -hDEC mAbs ligated to short fluorescent peptide. Sample was analyzed on a C4 column using a linear gradient of 5-75% solvent D in solvent C over 30 min at 55 °C and monitored at 280 nm. MS analysis of the heavy chain peak confirmed formation of the desired ligation product (MW = 50529.4 Da, MW<sub>calcd</sub> = 50526.3) as well as the presence of unmodified heavy chain (MW = 49825.6 Da, MW<sub>calcd</sub> = 49823.2 Da), which had originated from hydrolysis of the intein fusion during expression and purification (Supplementary Fig. 1 a-b). (c) SEC-MALS analysis of  $\alpha$ -hDEC mAb ligated to short fluorescent peptide confirms that the antibody remains mono-disperse (poly-dispersity index = 1.007) after thiolysis and ligation. Measured MW was 164 kDa (MW<sub>calcd</sub> = 150 kDa).

## Supplementary Figure 4




**Supplementary Figure 4. Synthesis of Cys-ds-DNA:** Fmoc-Cys(StBu)-OSu (**5**) was coupled to a poly-A oligo (Fisher Scientific) bearing the Amino-C6 Modifier at its 5' end (**6**), in a 50% DMF/borate buffer pH 8.5 (i). After RP-HPLC purification (ii) the Fmoc and StBu protecting groups of **7** were removed by treatment with 30% aqueous  $\text{NH}_4\text{OH}$  (iii) and 1 M DTT (iv), respectively. Following complete deprotection, the Cys-poly-A (**8**) was annealed to its complementary poly-T strand by mixing them at a 1:1 ratio and heating them up at 95 °C followed by slow cooling to room temperature over 1 h. The Cys-ds-polyA-T (**9**) was directly used in the ligation reactions.

## Supplementary Figure 5




**Supplementary Figure 5. Production of mAb-ds-DNA conjugates.** (a) The mAb-thioester derivatives were mixed with 20 bp DNA oligo (dA:dT) containing a cysteine residue at the 5' end of the dA oligo. Production of mAb-dA:dT conjugates was monitored on a 4-20% TBE native gel stained with ethidium bromide. Samples were left untreated (-) or treated with Proteinase K (+) to confirm the presence of mAb-DNA conjugates. Numbers are expressed in bp based on markers. Cys-DNA alone (DNA) is shown for comparison. (b) Indirect estimate of mAb-DNA ligation efficiency using a chase reaction. The indicated mAb-thioester was reacted with Cys-DNA for 18 hrs after which the fluorescent peptide (1,000 pmoles, 20 fold excess) was added and allowed to react for a further 18 hrs. The reaction mixtures were then resolved on a 10% SDS PAGE. Numbers at the top are pmoles of fluorescent peptide used to generate a standard curve. + indicates direct fluorescent labeling of the mAb, i.e., no chase. R corresponds to the actual mAb-DNA reaction followed by the chase. (c) Ligated  $\alpha$ -hDEC-dA:dT mAbs was analyzed by SEC-MALS. The conjugate runs as a single peak with a polydispersity index of 1.005 and a measured MW of 185 KDa ( $MW_{\text{calcd}} = 172$  KDa). No aggregates could be detected after 24 hrs incubation at room temperature. (d) Purified mAb-dA:dT conjugates were reacted with Klenow Pol-I fragment in the presence of dATP and dTTP for the indicated times in minutes. Aliquots of elongation reaction were treated with proteinase K and run on a 2% agarose gel stained with EtBr. Numbers are expressed in bp based on markers.

## Supplementary Figure 6



**Supplementary Figure 6. Blocking of RIG-I in MoDCs using siRNA.** Quantitative PCR was performed to determine the relative mRNA levels of RIG-I (gray) and MDA5 (blue) in MoDCs treated with RIG-I, MDA5, and control siRNA (treatment). Histograms show the mean  $\pm$  SD of 2 experiments with a total of 3 samples each.


**Supplementary Figure 7**



**Supplementary Figure 7.  $\alpha$ -mDEC-pdA:dT mAbs induce less hypothermia than Poly I:C.** B6 mice were inoculated i.p. with indicated immune stimulants (10  $\mu$ g), and the temperature of each mouse was determined 5-6 hrs after. Shown is the mean  $\pm$  SD of 2 experiments with 6 animals total in each group. In all cases, statistical differences were determined between all groups. p values of  $\leq 0.01$  (\*\*) and 0.001 (\*\*\*) are indicated; n.s. is non-significant.




**Supplementary Figure 8**



**Supplementary Figure 8.  $\alpha$ -mDEC-pdA:dT mAbs triggers type I IFN production *in vivo*.** B6 or DEC KO mice were lethally irradiated and injected with bone marrow cells from DEC KO mice (KO  $\rightarrow$  B6) or B6 mice (B6  $\rightarrow$  KO), respectively. 12-14 weeks after bone marrow transplant, chimeras were inoculated with 10  $\mu$ g of  $\alpha$ -mDEC-pdA:dT mAbs. As controls, we also inoculated B6 mice and DEC KO mice. 12 hrs after inoculation serum was collected and production of IFN- $\beta$  was evaluated by ELISA. Shown is the mean  $\pm$  SD of two experiments with a total of 4 mice per group.


## Supplementary Figure 9



### Supplementary Figure 9. Targeting adjuvant and antigen to DCs induces CD4 T cell immunity.

B6 mice were primed and boosted 4 wks apart with 5  $\mu$ g of HIV Gag-p24 antigen fused to  $\alpha$ -mLangerin mAbs. 15  $\mu$ g of  $\alpha$ -mDEC-pdA:dT mAbs, 7.5-15  $\mu$ g of poly I:C, or 15  $\mu$ g of mControl Ig-pdA:dT mAbs was used as the adjuvant. Seven days after boost, splenocytes were restimulated *in vitro* with the reactive HIV Gag-p24 peptide mix (p24) or a non-reactive HIV Gag-p17 peptide pool (p17, negative control), in the presence of Brefeldine A (BFA) for 6 hrs. Intracellular staining was performed to detect IFN $\gamma$  in CD3<sup>+</sup> CD4<sup>+</sup> gated T cells. The % of IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cells is shown as the mean  $\pm$  SD of 3 independent experiments with a total of 6 mice.

## Supplementary Figure 10



**Supplementary Figure 10. Proposed mechanism of DC activation by  $\alpha$ -DEC-pdA:dT mAbs.** Targeted delivery of ds-DNA adjuvant to DEC expressing DCs using  $\alpha$ -DEC-pdA:dT mAbs. Upon binding to the cognate receptor and endocytosis of the  $\alpha$ -DEC-ds-DNA complexes, the DNA is released into the cytoplasm, transcribed into ds-RNA, which then activates pattern recognition receptors (PRR) such as RIG-I, leading to immune activation.